Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 exon 20 insertion
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 exon 20 insertion
Solid Tumor
HER-2 exon 20 insertion
Solid Tumor
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
poziotinib
Sensitive: C2 – Inclusion Criteria
poziotinib
Sensitive
:
C2
poziotinib
Sensitive: C2 – Inclusion Criteria
poziotinib
Sensitive
:
C2
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
DZD9008
Sensitive: C2 – Inclusion Criteria
DZD9008
Sensitive
:
C2
DZD9008
Sensitive: C2 – Inclusion Criteria
DZD9008
Sensitive
:
C2
HER-2 exon 20 insertion
Lung Adenocarcinoma
HER-2 exon 20 insertion
Lung Adenocarcinoma
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
rivoceranib + pyrotinib
Sensitive: C3 – Early Trials
rivoceranib + pyrotinib
Sensitive
:
C3
rivoceranib + pyrotinib
Sensitive: C3 – Early Trials
rivoceranib + pyrotinib
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
KN046
Sensitive: C3 – Early Trials
KN046
Sensitive
:
C3
KN046
Sensitive: C3 – Early Trials
KN046
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
HER-2 exon 20 insertion
HER2 Negative Breast Cancer
HER-2 exon 20 insertion
HER2 Negative Breast Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
HER-2 exon 20 insertion
Lung Adenocarcinoma
HER-2 exon 20 insertion
Lung Adenocarcinoma
afatinib
Sensitive: C4 – Case Studies
afatinib
Sensitive
:
C4
afatinib
Sensitive: C4 – Case Studies
afatinib
Sensitive
:
C4
HER-2 exon 20 insertion
HER2 Positive Breast Cancer
HER-2 exon 20 insertion
HER2 Positive Breast Cancer
neratinib + ado-trastuzumab emtansine
Sensitive: D – Preclinical
neratinib + ado-trastuzumab emtansine
Sensitive
:
D
neratinib + ado-trastuzumab emtansine
Sensitive: D – Preclinical
neratinib + ado-trastuzumab emtansine
Sensitive
:
D
HER-2 exon 20 insertion
HER2 Positive Breast Cancer
HER-2 exon 20 insertion
HER2 Positive Breast Cancer
neratinib + fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
neratinib + fam-trastuzumab deruxtecan-nxki
Sensitive
:
D
neratinib + fam-trastuzumab deruxtecan-nxki
Sensitive: D – Preclinical
neratinib + fam-trastuzumab deruxtecan-nxki
Sensitive
:
D
HER-2 exon 20 insertion
Lung Adenocarcinoma
HER-2 exon 20 insertion
Lung Adenocarcinoma
poziotinib
Sensitive: D – Preclinical
poziotinib
Sensitive
:
D
poziotinib
Sensitive: D – Preclinical
poziotinib
Sensitive
:
D
HER-2 exon 20 insertion
Solid Tumor
HER-2 exon 20 insertion
Solid Tumor
TAS2940
Sensitive: D – Preclinical
TAS2940
Sensitive
:
D
TAS2940
Sensitive: D – Preclinical
TAS2940
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login